Certified by Founder
Lodge
Dispatch Bio
start up
- 24/07/2025
- Series A
- Undisclosed Amount
Established in 2022, Dispatch Bio was founded with a bold purpose: to help create a world where all cancer patients can be cured. To achieve this, the company is engineering a universal treatment across solid tumors, leveraging its first-in-class Flare platform. This novel approach combines the strengths of immunotherapy with a tumor-specific viral vector, both engineered to clear tumor cells with precision and power. Dispatch has operations in Philadelphia and San Francisco, with access to world-class researchers.
- Industry Biotechnology Research
- Website https://dispatchbio.com/
- LinkedIn https://www.linkedin.com/company/dispatch-bio/
Foreverland Food | $6,956,279 | (Mar 24, 2026)
Meadow Memorials | $9,000,000 | (Mar 24, 2026)
Oryon Cell Therapies | $21,000,000 | (Mar 24, 2026)
Hamilton AI | $7,500,000 | (Mar 24, 2026)
Flourish Care | $5,700,000 | (Mar 24, 2026)
Interloom | $16,500,000 | (Mar 24, 2026)
EGIDE | $9,266,200 | (Mar 24, 2026)
Cleavr | $1,158,600 | (Mar 24, 2026)
SPARK Microsystems | $12,364,525 | (Mar 24, 2026)
JAAQ | $17,416,100 | (Mar 24, 2026)
CisLunar Industries | $2,600,000 | (Mar 24, 2026)